Chonluten T-34 20mg – EDG Tripeptide | Biotech Peptides

$62.00

Buy Chonluten T-34 20mg for laboratory research. Review the EDG tripeptide reference sequence, molecular formula, and published in-vitro research context.

SKU: Chonluten-T-34-20mg Category:
Description

Chonluten (T-34) (20mg) – EDG Tripeptide for Laboratory Research

Chonluten (T-34) is listed by Biotech Peptides as a 20mg research product. In the published literature, Chonluten is identified as the short tripeptide Glu-Asp-Gly (EDG). This peptide has been investigated in laboratory research on monocyte and macrophage inflammatory signalling, including cellular responses to bacterial lipopolysaccharide (LPS).

The information below describes the reference tripeptide and published research. It should not be interpreted as confirmation of the composition, purity, salt form, or measured peptide content of a particular product batch.

Reference Chemical Information

Property Reference information
Product name Chonluten (T-34)
Listed quantity 20mg
Peptide sequence Glu-Asp-Gly
One-letter sequence EDG
Peptide length 3 amino acids
Molecular formula C₁₁H₁₇N₃O₈
Molecular weight Approximately 319.27 g/mol
CAS number 75007-24-8
PubChem CID 194641
Reference structure H-Glu-Asp-Gly-OH

These values describe the unmodified reference tripeptide recorded as glutamyl-aspartyl-glycine. They are not batch-specific analytical results and do not establish the counterion, residual water, purity, or net peptide content of the listed material. See the PubChem reference record.

Published Research Context

Monocyte and macrophage signalling

A 2022 study by Avolio and colleagues examined five short peptides, including Chonluten, in the human THP-1 monocytic cell line and its differentiated macrophage model. The researchers investigated cellular signalling and inflammatory responses under laboratory conditions, including exposure to LPS.

The paper reports that Chonluten affected TNF production in the cell model. The broader experiments also examined TNF and IL-6 expression and the adhesion of treated cells to activated endothelial-cell layers. These findings provide an in-vitro research context for studying Chonluten and inflammatory signalling; they do not demonstrate a clinical effect or establish efficacy in respiratory disease.

Primary study: Avolio et al. (2022), Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line, International Journal of Molecular Sciences.

Research Scope and Limitations

The published THP-1 findings are cell-culture observations. They should not be presented as proof that Chonluten treats inflammation, asthma, chronic obstructive pulmonary disease (COPD), respiratory infections, or any other condition.

The study does not establish human clinical effectiveness, safety, or an approved medical application. Results from a cell-line model also cannot automatically be generalised to intact tissues, animals, or people.

Product Documentation

The listed product quantity is 20mg. Product-specific details—including the actual supplied composition, salt or counterion form, purity, identity testing, and batch content—should be confirmed against current manufacturer documentation.

A reference molecular formula or molecular weight is not a substitute for a lot-specific Certificate of Analysis (COA). No batch-specific analytical results are provided here.

For additional laboratory materials, explore the Biotech Peptides research peptide collection.

For laboratory and analytical research only. Not for human or animal consumption, personal administration, medical treatment, diagnosis, or veterinary application. Review the Research Use Only notice before ordering.

Additional information
BrandBiotech Peptides
Shipping & Delivery